CLSA Events, Home Events

Daiichi Sankyo Partnering Day

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.

Through the outstanding knowledge and commitment of our 30,000 employees worldwide, we create innovative new medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

Our successes include the antihypertensive agent olmesartan (Benicar®), launched in 2002 and now available in more than 80 countries around the world; the antiplatelet agent prasugrel (Effient®), launched in 2009 for patients with acute coronary syndrome undergoing percutaneous coronary intervention, and edoxaban, the first available factor Xa inhibitor in Japan, which launched in 2011 to help prevent venous thromboembolism.

To reinforce the competitiveness of research in disease areas with high unmet medical needs, we are also focused on discovering and developing novel oncology and cardiovascular-metabolic therapies and substances with novel mechanisms of action.
We are partnering on promising products that complement our in-house portfolio and will help us achieve long-term growth. Our strategy involves acquiring new products and product candidates, and companies that will drive our portfolio in key therapeutic areas. We have a long-history of effective collaboration, exemplifying our ability to license products in and out of Daiichi Sankyo while developing and maintaining valuable partnerships throughout the industry.

For more information about our partnering activities, please visit at
For more information about our clinical stage pipeline, please visit at

Confirmed Daiichi Sankyo Participants

Mahmoud Ghazzi, MD, PhD
Executive Vice President and Global Head of Development

Jeffrey W. Warmke, PhD
Senior Vice President, External Scientific Affairs

Michele Mercuri, MD, PhD
Vice President, Clinical Development Cardiovascular
(Cardiovascular TA Head)

Fujio Isono, PhD
Vice President, Frontier Research Laboratories
(Frontier TA Head)

Archie Tse, MD, PhD
Senior Director, Clinical Development Oncology
(Oncology TA Head)

Stuart J. Mackey
Executive Vice President and Global Head of Business Development

Kazuo Sato, PhD
Corporate Officer and Vice President of Business Development

Kenneth Truit, MD
Vice President, Translational Medicine & Clinical Pharmacology

Mark Marino, MD
Vice President, Clinical Development Endocrine/Metabolic/Immunology

Reinhard Von Roemeling, MD
Vice President, Clinical Development Oncology


Daiichi Sankyo Partnering Day


Wednesday, February 5, 2014
Business Development Reception
(Open Admission)

Thursday, February 6, 2014
Plenary Session: Daiichi Sankyo Corporate Overview
(open admission)
Welcome and Introductions – Stuart Mackey
Company Overview – Dr. Mahmoud Ghazzi
Oncology Therapeutic Area Overview – Dr. Archie Tse
Cardiovascular Metabolic Therapeutic Area Overview – Dr. Michele Mercuri
Frontier Therapeutic Area Overview – Dr. Fujio Isono
Partnering with Daiichi Sankyo – Stuart Mackey
Open Q&A Session – Stuart Mackey

One-on-one Meetings
(application required)


San Mateo Marriott
1770 South Amphlett Blvd
San Mateo, CA 94402


$3 per hour on-site parking available


Registration is closed.

Attire:Business attire suggested

Please contact Amanda Detzel at or 650-871-3257 for further information.

Is your company a member? Click here to check.

See how your company can save money by becoming a BayBio member!